menu
    • menu
    [{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Licensing Agreement","leadProduct":"BND-22","moa":"ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Deep Insight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2021","type":"Series C Financing","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Deep Insight","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Deep Insight"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2025","type":"Termination","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":1.1299999999999999,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.1299999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Sanofi","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"BND-22","moa":"||ILT-2 receptor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Biond Biologics \/ Sanofi","highestDevelopmentStatusID":"7","companyTruncated":"Biond Biologics \/ Sanofi"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Inapplicable","leadProduct":"BND-35","moa":"||LT3\/LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biond Biologics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biologics \/ Inapplicable"},{"orgOrder":0,"company":"Biond Biologics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Other Large Molecule","year":"2024","type":"Collaboration","leadProduct":"BND-35","moa":"||LT3\/LILRB4","graph1":"Oncology","graph2":"Phase I","graph3":"Biond Biologics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biond Biologics \/ Merck Group","highestDevelopmentStatusID":"6","companyTruncated":"Biond Biologics \/ Merck Group"}]

    Find Clinical Drug Pipeline Developments & Deals by Biond Biologics

    Menu

    Biond Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BND-22,Cetuximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : $1,125.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            Biond Biologics Regains Full Rights to BND-22, Targeting ILT2 Receptor

                            Details : Through the termination, Bioned will regain the full rights of SAR444881 (BND-22) from Sanofi. It is being evaluated for the treatment of Advanced Solid Tumors.

                            Product Name : SAR444881

                            Product Type : Antibody

                            Upfront Cash : $125.0 million

                            March 03, 2025

                            Lead Product(s) : BND-22,Cetuximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : $1,125.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BND-35,Cetuximab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Biond Biologics And Merck Partner on BND-35 Trial for Solid Tumors

                            Details : The collaboration aims to evaluate BND-35 in combination with Merck's anti-EGFR monoclonal antibody Erbitux (cetuximab) in a Phase 1 for unresectable or metastatic solid tumors.

                            Product Name : BND-35

                            Product Type : Other Large Molecule

                            Upfront Cash : Undisclosed

                            October 29, 2024

                            Lead Product(s) : BND-35,Cetuximab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Merck Group

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BND-35,Nivolumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biond Biologics Announces First Patient Dosed with BND-35 in Phase 1 Clinical Trial

                            Details : BND-35 is a novel anti-ILT3/LILRB4 antagonist antibody, it is being developed in combination with Nivolumab for the treatment of solid tumors.

                            Product Name : BND-35

                            Product Type : Other Large Molecule

                            Upfront Cash : Inapplicable

                            June 24, 2024

                            Lead Product(s) : BND-35,Nivolumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BND-22,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biond Biologics Announces First Patients Dosed with BND-22 (SAR444881) Combinations in Phase 1 Clinical Trial

                            Details : BND-22 (SAR444881), is a humanized IgG4, antagonist antibody targeting the ILT2 receptor in development for the treatment of solid tumors, is an inhibitory receptor expressed on both innate and adaptive immune cells that binds MHC class I molecules.

                            Product Name : BND-22

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            May 23, 2022

                            Lead Product(s) : BND-22,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BND-22,Cetuximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biond Biologics to Present at the Raymond James LILRB/ILT Symposium

                            Details : BND-22 (SAR444881), a novel immune checkpoint inhibitor targeting the Immunoglobulin-like transcript receptor 2 or ILT2, enhances anti-tumor activity of T cells and NK cells.

                            Product Name : BND-22

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            April 20, 2022

                            Lead Product(s) : BND-22,Cetuximab,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Sanofi

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BND-22

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Sanofi

                            Deal Size : $1,125.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND22, a Novel Immune Checkpoint Inhibito...

                            Details : BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.

                            Product Name : BND-22

                            Product Type : Antibody

                            Upfront Cash : $125.0 million

                            December 01, 2021

                            Lead Product(s) : BND-22

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Sanofi

                            Deal Size : $1,125.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed

                            Biond Biologics

                            Israel arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BND-22,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Deep Insight

                            Deal Size : $15.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            Biond Biologics Announces Closing of $15 Million Series C Financing

                            Details : The financing has sopported the development of BND-22 (SAR444881), the company’s Ig-Like Transcript 2 (ILT2) receptor-blocking antibody, and the first patient has been dosed in the first-in-human, phase 1 clinical trial of BND22.

                            Product Name : BND-22

                            Product Type : Antibody

                            Upfront Cash : Undisclosed

                            March 11, 2021

                            Lead Product(s) : BND-22,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Deep Insight

                            Deal Size : $15.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth